Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

NCT04762979 is registered in ClinicalTrials.gov with Marina N Sharifi as lead sponsor.

NCT NCT04762979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04762979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Lead sponsor
Marina N Sharifi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 12, 2021
Completion date
May 31, 2026
Enrollment
44 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer, hormone receptor positive breast carcinoma, pik3ca mutant metastatic breast cancer